Jaguar Health announced that the required procedure of registering the source of the active pharmaceutical ingredient of crofelemer with the Agenzia Italiana Del Farmaco, the Italian Medicines Agency, has been completed. Resultingly, batches of crofelemer API manufactured by Milan, Italy-based Indena S.P.A. can now be used by Jaguar for further development work.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JAGX:
- Jaguar Health announces board for JV Magdalena Biosciences
- Jaguar Health to hold an investor webcast
- Jaguar Health appoints Sandra Swain to scientific advisory board
- Jaguar Health, Filament Health form joint venture Magdalena Biosciences
- Jaguar Health provides updates on crofelemer for pediatric SBS, CDD